Verve Therapeutics, Inc. (VERV) announced on Tuesday that it would stop enrolling participants in its Heart-1 Phase 1b trial of VERVE-101, under its PCSK9 gene therapy program due to an adverse event in the sixth patient who received a 0.45 mg/kg dose. Subsequently, the stock is down 37%. The company is reviewing the laboratory data and has stated its intention to collaborate with health authorities to determine the next steps for VERVE-101.

Verve Therapeutics，Inc.（VERV）周二宣布，由于第六名接受0.45 mg/kg剂量的患者出现不良事件，该公司将停止招募参与者参加其PCSK9基因治疗计划下的Verve-101 Heart-1 1b期试验。随后，该股下跌了37%。该公司正在审查实验室数据，并表示打算与卫生部门合作，以确定VERVE-101的下一步行动。

Meanwhile, the company is focusing on advancing the development of VERVE-102 and launching the Heart-2 clinical trial in the second quarter of this year. VERVE-102 utilizes the same fundamental editing tools and guide RNA for PCSK9 as VERVE-101, but employs a different lipid nanoparticle delivery method..

与此同时，该公司正致力于推进VERVE-102的开发，并于今年第二季度启动Heart-2临床试验。VERVE-102使用与VERVE-101相同的基本编辑工具和PCSK9的指导RNA，但使用不同的脂质纳米颗粒递送方法。。

VERV is trading on the Nasdaq at $7.97, down 37.72% or $4.82 per share. It has traded between $8.22 and $21.42 in the past 52-week period. For comments and feedback contact: editorial@rttnews.comBusiness News

VERV在纳斯达克的交易价格为7.97美元，下跌37.72%，即每股4.82美元。在过去52周内，它的交易价格在8.22美元至21.42美元之间。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

使用RTT Intelligent Investor访问溢价股票警报。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股